Investors Buy High Volume of Put Options on Hologic (NASDAQ:HOLX)

Hologic, Inc. (NASDAQ:HOLX) was the recipient of unusually large options trading activity on Monday. Investors acquired 3,509 put options on the company. This represents an increase of 207% compared to the typical volume of 1,144 put options.

Institutional Investors Weigh In On Hologic

Institutional investors and hedge funds have recently bought and sold shares of the business. NewEdge Wealth LLC grew its position in shares of Hologic by 3.8% in the 3rd quarter. NewEdge Wealth LLC now owns 3,779 shares of the medical equipment provider’s stock worth $281,000 after buying an additional 138 shares during the last quarter. Allworth Financial LP raised its holdings in shares of Hologic by 8.1% during the fourth quarter. Allworth Financial LP now owns 1,890 shares of the medical equipment provider’s stock valued at $141,000 after acquiring an additional 141 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. raised its holdings in shares of Hologic by 1.9% during the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 7,675 shares of the medical equipment provider’s stock valued at $572,000 after acquiring an additional 142 shares in the last quarter. BCS Private Wealth Management Inc. lifted its stake in Hologic by 2.5% in the fourth quarter. BCS Private Wealth Management Inc. now owns 6,105 shares of the medical equipment provider’s stock worth $455,000 after acquiring an additional 150 shares during the period. Finally, Savant Capital LLC boosted its holdings in Hologic by 0.9% in the third quarter. Savant Capital LLC now owns 19,776 shares of the medical equipment provider’s stock valued at $1,335,000 after acquiring an additional 170 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hologic in a report on Wednesday, January 28th. Evercore downgraded shares of Hologic from an “outperform” rating to an “in-line” rating and lowered their price target for the stock from $79.00 to $78.00 in a research note on Monday, January 5th. Finally, Argus cut Hologic from a “buy” rating to a “hold” rating in a research note on Monday, January 12th. Two analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $78.42.

Hologic Trading Up 0.5%

HOLX stock traded up $0.37 during midday trading on Monday, hitting $76.02. The company had a trading volume of 22,469,730 shares, compared to its average volume of 3,022,236. The stock has a market cap of $16.97 billion, a price-to-earnings ratio of 31.67, a PEG ratio of 2.24 and a beta of 0.70. Hologic has a 52 week low of $51.90 and a 52 week high of $76.07. The company has a current ratio of 4.04, a quick ratio of 3.32 and a debt-to-equity ratio of 0.48. The stock’s 50 day moving average price is $75.28 and its 200 day moving average price is $73.71.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). The firm had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.07 billion. Hologic had a return on equity of 19.58% and a net margin of 13.18%.Hologic’s revenue was up 2.5% on a year-over-year basis. During the same period last year, the business earned $0.87 EPS. As a group, equities research analysts expect that Hologic will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.